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Background: During pregnancy, patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) can
experience active disease, which might be influenced by adjustment of treatment around conception. The aim of
this study was to identify possible risk factors of disease flares during pregnancy and to evaluate the effect of
treatment in pregnant patients experiencing a flare.
Methods: Pregnant patients with RA and axSpA were prospectively followed before, during, and after pregnancy.
Disease activity and flares of disease activity were analyzed in regard to medication.
Results: Among 136 pregnant patients, disease flares during pregnancy occurred in 29% of patients with RA and in
25% of patients with axSpA. In both diseases, active disease and tumor necrosis factor inhibitor (TNFi) discontinuation
in early pregnancy were identified as risk factors for disease flares during pregnancy. Of 75 patients with RA, 15 patients
were on TNFi and discontinued the treatment at the time of the positive pregnancy test. After stopping TNFi, disease
activity increased, which was reflected by peaking C-reactive protein levels at the first trimester. The relative risk of flare
in patients with RA stopping TNFi was 3.33 (95% CI 1.8–6.1). Initiation of TNFi or glucocorticosteroid (GC) treatment in
60% of these patients resulted in disease improvement at the second and third trimesters. In comparison, patients with
RA without TNFi in the preconception period, most of whom had used pregnancy-compatible antirheumatic drugs,
showed mild and stable disease activity before and during pregnancy. Of 61 patients with axSpA, 24 patients were on
TNFi and discontinued the treatment at the time of the positive pregnancy test. In patients with axSpA stopping TNFi,
a disease aggravation at the second trimester could be observed. The relative risk of flare in this group was 3.08 (95%
CI 1.2–7.9). In spite of initiated TNFi or GC treatment in 62.5% of these patients, disease activity remained elevated
throughout pregnancy. Patients with axSpA without TNFi in the preconception period showed persistent high disease
activity from prepregnancy until the postpartum period.
Conclusions: On the basis of a risk-benefit analysis, to stabilize disease activity and to prevent a flare during pregnancy
in patients with RA and axSpA, tailored medication including TNF inhibitors should be considered beyond conception.
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Rheumatoid arthritis (RA) and axial spondyloarthritis
(axSpA) often affect women of childbearing age. In pa-
tients wishing for children, pregnancy represents a chal-
lenge in the management of the disease because current
disease activity, the influence of pregnancy on the dis-
ease, and the safety of antirheumatic drugs in pregnancy
have to be taken into account [1]. During pregnancy,
active disease can be found in about 35% to 52% of
patients with RA and in 60% to 80% of patients with
axSpA [2–5].
In RA, the positivity for or elevated level of rheuma-
toid factor or anticitrullinated antibodies is associated
with more active disease during pregnancy [6, 7]. Dis-
ease activity before conception seems to be an additional
factor that influences the disease course during preg-
nancy in patients with RA because quiescent disease
often remains stable throughout pregnancy [3]. Active
disease or flares during pregnancy in patients with
rheumatic disease can harm maternal and fetal health
and should therefore be avoided.
Up to now, it is unknown whether changes of treat-
ment before conception or early in pregnancy have an
influence on the disease course during pregnancy in pa-
tients with RA and axSpA. This information would be of
clinical importance, however, in the management of pa-
tients with RA and axSpA before and during pregnancy.
The aim of this study was to analyze the frequency of
flares during pregnancy in patients with RA and axSpA
and to delineate risk factors for flares. In addition, we
analyzed the response to therapy in controlling disease




In total, 136 pregnant patients with RA or axSpA were
prospectively followed between 2000 and 2015 at the
Center for Pregnancy in Rheumatic Diseases at the
Department of Rheumatology of the Inselspital Bern,
Switzerland. Patients with RA had to fulfill the revised
1987 American College of Rheumatology classification
criteria for RA [8]. Patients with spondyloarthritis (SpA)
fulfilled the European Spondylarthropathy Study Group
criteria for SpA [9]. All patients with SpA also fulfilled
the Assessment of SpondyloArthritis international Society
(ASAS) criteria for axSpA; for patients recruited before
2009, the ASAS criteria were applied in retrospect [10].
The study was approved by the ethics committee of the
Canton of Bern, Switzerland, and patients were included
after they provided written informed consent. Patients
were examined within 6 months before conception, at each
trimester (gestational weeks 10–12, 20–22, and 30–32) and
6–8 weeks postpartum. At each visit, detailed informationon medication, disease activity, and pregnancy were re-
corded. Flare was analyzed at each visit during pregnancy
and postpartum. If demanded by maternal disease, tumor
necrosis factor inhibitor (TNFi) or glucocorticosteroid
(GC) treatment was initiated during pregnancy, based on a
risk-benefit analysis as well as informed and shared deci-
sion making.
Assessments and definitions
In patients with RA, disease activity states were assessed
by the three-variable Disease Activity Score in 28 joints
based on C-reactive protein (DAS28-CRP) [11]. DAS28-
CRP scores below 2.6 were defined as clinical remission,
DAS28-CRP scores from 2.7 to 3.2 as low disease activ-
ity, DAS28-CRP scores from 3.3 to 5.1 as intermediate
disease activity, and DAS28-CRP scores above 5.1 as
high disease activity [11]. Flare was defined by an
increase of DAS28-CRP greater than 0.6 [12] in combin-
ation with an elevated C-reactive protein (CRP) level.
Active disease was defined by DAS28-CRP scores higher
than 3.2. In patients with axSpA, disease activity states
were measured by the patient global assessment, the
Bath Ankylosing Spondylitis Disease Activity Index, and
the Ankylosing Spondylitis Disease Activity Score based
on C-reactive protein (ASDAS-CRP). In patients with
axSpA recruited before the development of the ASDAS-
CRP in 2009 [13], the ASDAS-CRP scores were calcu-
lated retrospectively. Categories of the ASDAS-CRP
were defined as inactive disease for scores below 1.3,
moderate disease activity for scores from 1.3 to 2.0, high
disease activity for scores from 2.1 to 3.5, and very high
disease activity for scores above 3.5 [14]. Active disease
was defined by ASDAS-CRP scores higher than 2.1. Flare
of disease activity was defined by an increase of ASDAS-
CRP greater than 0.6 in combination with an elevated CRP
level. A flare during pregnancy was defined as a flare ob-
served during the first, second, or third trimester.
Statistical analysis
For longitudinal comparisons of paired samples, the
Wilcoxon signed-rank test was used. The Mann-Whitney
U test was performed to analyze unpaired data as well as
in groupwise comparisons. To analyze categorical data,
Fisher’s exact test was performed. A significant difference
was considered in case of P values less than 0.05.
Results
Flare rates during pregnancy in patients with RA and
axSpA are associated with active disease and TNFi
discontinuation in early pregnancy
A total of 136 pregnant patients were identified, com-
prising 75 patients with RA and 61 patients with axSpA.
Patients’ characteristics and medical treatment at base-
line are displayed in Table 1.
Table 1 Patients’ characteristics and treatments before conception
RA (n = 75) axSpA (n = 61)
Age at conception, years (median) 31 (21–40) 31 (22–41)
Age at diagnosis, years (median) 27 (20–38) 24 (17–33)
Rheumatoid factor-positive 50 (66) –
HLA-B27-positive – 43 (70.5)
axSpA with peripheral arthritis – 27 (44.3)
Medication within 3 months before conception
Methotrexatea 2 (2.7) –
NSAIDs 8 (10.7) 18 (29.5)
TNFib 15 (20.0) 24 (39.3)
Glucocorticosteroidsc 25 (33.3) 5 (8.2)
DMARDs 29 (38.7) 5 (8.2)
SSZ 18 (24.0) 5 (8.2)
HCQ 8 (10.7)
SSZ and HCQ 3 (4.0)
Abbreviations: axSpA Axial spondyloarthritis, DMARD Disease-modifying
antirheumatic drug, HCQ Hydrochloroquine, HLA Human leukocyte antigen, NSAID
Nonsteroidal anti-inflammatory drug, RA Rheumatoid arthritis, SSZ Sulfasalazine,
TNFi Tumor necrosis factor inhibitor
aMethotrexate, discontinued 1 month before the planned conception
bTNFi, discontinued at the time of the positive pregnancy test
cPrednisone or prednisolone
van den Brandt et al. Arthritis Research & Therapy  (2017) 19:64 Page 3 of 9Before pregnancy, 61 patients with RA had low disease
activity, and 8.6% had active disease with DAS28-CRP
scores greater than or equal to 3.2. However, during
pregnancy, a flare of disease activity occurred in 29% of
patients with RA. Most flares emerged in the first tri-
mester (Table 2). No patient with RA experienced more
than one episode of flare during pregnancy. Comparing
patients with flares with those without them, the discon-
tinuation of TNFi in early pregnancy correlated with the
risk of flares (P = 0.001) (Table 3). Flares during the
course of pregnancy were also associated with elevated
disease activity and CRP at early pregnancy (P = 0.038 and
P = 0.008, respectively) (Table 3 and Additional file 1:
Table S1).
During the prepregnancy period, patients with RA
treated with TNFi showed disease activity comparable to
that of patients without TNFi treatment during the same
period. Among the 15 patients treated with TNFi during
at least 20 weeks before conception, all discontinued the
treatment at the positive pregnancy test; the median
time point of discontinuation was gestational week 3.
After the discontinuation of TNFi, the relative risk of a
flare during pregnancy was 3.33 (95% CI 1.8–6.1).
Patients with RA who discontinued TNFi showed active
disease at the first trimester and peaking CRP levels
(P = 0.04 prepregnancy to first trimester, P = 0.03 first
trimester to second trimester) (Fig. 1). The aggravation of
disease activity led to a treatment adjustment in 60% ofthe patients. In most patients with RA without TNFi treat-
ment, disease activity remained stable throughout preg-
nancy, with DAS28-CRP scores ranging from 2.6 to 3.1
and low CRP levels (Fig. 1a, b). The therapies received by
patients with RA with and without TNFi are shown in
Table 2. Among patients without TNFi, a higher pro-
portion received pregnancy-compatible drugs such as
sulfasalazine, hydroxychloroquine, GCs, and nonsteroidal
anti-inflammatory drugs before and during pregnancy
than those treated with TNFi.
Among patients with axSpA, 24.6% showed active
disease with ASDAS scores greater than or equal to 2.1
before pregnancy. Flares of disease activity during preg-
nancy occurred in 25% of patients with axSpA and were
most often seen in the second half of pregnancy
(Table 2). The discontinuation of TNFi treatment at the
positive pregnancy test (P = 0.017), elevated CRP levels
(P = 0.006), and active disease at early pregnancy were
associate with flares during pregnancy in these women
(Table 3, Additional file 1: Table S1).
Among the 61 patients with axSpA, 24 patients
received TNFi treatment before pregnancy and had a
median ASDAS-CRP of 1.95 preconceptionally. After
discontinuation of TNFi treatment at the positive preg-
nancy test (median time point of discontinuation was
gestational week 3), the relative risk of flare was 3.08
(95% CI 1.2–7.9) (Table 3). Patients with axSpA who
discontinued TNFi treatment experienced high disease
activity throughout pregnancy, with ASDAS-CRP scores
ranging between 2.4 and 2.8 and CRP peaking at the
second trimester (Fig. 1c, d). There was no patient with
more than one flare episode during pregnancy. Among
patients with axSpA discontinuing TNFi, an initiation or
restart of medication was required in 62.5% during ges-
tation. In patients with axSpA without TNFi treatment,
ASDAS-CRP scores ranged from 2.2 to 2.7 throughout
pregnancy, and stable low CRP levels were measured. Of
these patients, 10.8% required a start of new medication
during pregnancy (Table 2). Comparing patients without
TNFi treatment and patients discontinuing TNFi
treatment at the positive pregnancy test, higher CRP
values were found in the latter group throughout preg-
nancy (P = 0.04 for first trimester, P = 0.03 for second
trimester, P = 0.01 for third trimester) (Fig. 1d).
Response to initiation of TNFi or GC treatment during
pregnancy
During pregnancy, 25 patients with RA (flare in n = 22, in-
crease of disease activity in n = 3) and 19 patients with
axSpA (flare in n = 15, increase of disease activity in n = 4)
experienced a disease aggravation with the need to step
up medication. Among patients with RA, 9 patients
started TNFi treatment and 16 started GC treatment dur-
ing pregnancy (Table 2). Upon TNFi treatment, median
Table 2 Flares and medical treatments during pregnancy in patients with and without tumor necrosis factor inhibitor use until
early pregnancy
RA axSpA
TNFi until positive pregnancy
testa (n = 15)
TNFi-negative
(n = 60)
TNFi until positive pregnancy
test (n = 24)
TNFi-negative
(n = 37)
Patients (n) with flare at
First trimester 6 4 1 2
Second trimester 3 4 5 1
Third trimester 1 4 4 2
Medication at conception
TNFi 15 (100) 0 (0) 24 (100) 0 (0)
NSAIDs 1 (6.7) 13 (21.7) 11 (45.8) 23 (61.2)
Glucocorticosteroidsb 1 (6.7) 23 (38.3) 2 (8.3) 1(3.7)
DMARDs 2 (13.3) 27 (45) 3 (12.5) 2 (5.4)
SSZ 1 (6.7) 17(28.3) 3 (12.5) 2 (5.4)
HCQ 1 (6.7) 7 (11.7)
SSZ and HCQ 3 (5)
Medication during pregnancy
TNFi 4 (26.7) 5 (8.3) 10 (41.7) 1 (2.7)
NSAIDs 5 (33.3) 23 (38.3) 15 (62.5) 27 (73)
Glucocorticosteroidsb 7 (46.7) 29 (48.3) 12 (50.0) 3 (8.1)
DMARDs 7 (46.7) 38 (63.3) 3 (12.5) 2 (5.4)
SSZ 1 (6.7) 23 (38.3) 3 (12.5) 2 (5.4)
HCQ 1 (6.7) 9 (15)
SSZ and HCQ 5 (33.3) 6 (10)
Initiation of medication during pregnancy 9 (60) 16 (26.7) 15 (62.5) 4 (10.8)
TNFic 4 (26.7) 5 (8.3) 10 (41.7) 1 (2.7)
Start at visit 1 T-2 T-3 T 2-2-0 1-3-1 4-4-2 0-0-1
Glucocorticosteroidsb 5 (33.3) 11(18.6) 12 (50) 3 (8.1)
Start at visit 1 T-2 T-3 T 0-4-1 3-6-2 4-5-3 0-2-1
Abbreviations: axSpA Axial spondyloarthritis, DMARD Disease-modifying antirheumatic drug, HCQ Hydrochloroquine, NSAID Nonsteroidal anti-inflammatory drug,
RA Rheumatoid arthritis, SSZ Sulfasalazine, TNFi Tumor necrosis factor inhibitor, 1 T First trimester, 2 T Second trimester, 3 T Third trimester
Numbers are count or count (percent); the percentages are calculated for each column
aNSAIDs used until gestational week 32
bPrednisone or prednisolone
cTNFi initiated during pregnancy: 11 certolizumab, 8 etanercept, 1 adalimumab
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(P = 0.03) (Fig. 2a), and median DAS28-CRP scores de-
creased from 4.25 to 2.60. Upon initiation of GC treat-
ment in pregnant patients with RA, median CRP values of
13 mg/L decreased to normal levels (P = 0.04) (Fig. 2b),
and DAS28-CRP dropped from 3.95 to 2.45, indicating in-
active disease.
Among patients with axSpA, TNFi treatment was initi-
ated in 11 and GC treatment in 15 during pregnancy
(Table 2). Upon initiation of TNFi, pregnant patients
with axSpA showed a significant decrease of median
CRP levels from 18.5 mg/L to 12 mg/L (P = 0.04)
(Fig. 2c). In spite of the improved CRP levels, disease ac-
tivity remained high, with slightly elevated CRP levelsand median ASDAS-CRP scores of 4.0 before and 3.7
after initiation of TNFi therapy (not shown). Upon GC
treatment, elevated CRP values persisted, with a median
CRP level of 12 mg/L (Fig. 2d) and a median ASDAS-
CRP score of 3.14.
Discussion
For the management of patients with RA and axSpA
who are planning a pregnancy, both disease activity and
therapeutic regimens have to be considered with regard
to maternal and fetal health. Any beneficial effect of
pregnancy on diseases such as RA could buffer a reduc-
tion of the antirheumatic therapy [2, 3, 7]. However, the
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Fig. 1 Disease activity over the course of pregnancy in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) treated with and without
tumor necrosis factor inhibitors (TNFi) until early pregnancy. Disease activity is compared between patients who received TNFi until the positive pregnancy
test and patients without TNFi treatment (TNFi-neg). The upper panels show Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP)
levels (a) and C-reactive protein (CRP) levels (b) in patients with RA (prepregnancy [pre]: number of patients [n] = 54, first trimester [1 T]: n= 59, second
trimester [2 T]: n= 66, third trimester [3 T]: n= 64, postpartum [pp]: n= 53). The lower panels display Ankylosing Spondylitis Disease Activity Score based on
C-reactive protein (ASDAS-CRP) levels (c) and CRP levels (d) in patients with axSpA (pre: n= 44, 1 T: n= 46, 2 T: n= 58, 3 T: n= 54, pp: n= 46). Box plots
present the medians and the interquartile ranges. *P< 0.051
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pecially in diseases such as axSpA, in which no major
beneficial effect has been observed during pregnancy
[15]. In the present study, disease flares during preg-
nancy were observed in 29% of patients with RA and
25% of patients with axSpA. Interestingly, our study
shows that, in the subgroup of patients with RA and
axSpA treated with TNFi for at least 5 months before
conception, the discontinuation of TNFi early in preg-
nancy could be a risk factor for disease flares during
pregnancy. Both groups of patients experienced an ag-
gravation of disease several weeks after withdrawal of
TNFi. Disease-specific characteristics as well as disease
activity at the time of TNFi withdrawal might play a role
in this respect because elevated disease activity in early
pregnancy is another risk factor for a flare during the
course of pregnancy. In nonpregnant patients with
axSpA, the discontinuation of TNFi leads to disease
flares in 76% to 100% [16]. In nonpregnant patients with
RA, the results vary with regard to whether the with-
drawal of TNFi may lead to a deterioration of disease ac-
tivity [17, 18]. Factors predictive of maintaining low
disease activity in RA include low disease activity at thetime of TNFi discontinuation [17]. However, others re-
port immediate disease deterioration in patients with
early RA in whom TNFi were withdrawn after they
achieved remission while receiving TNFi and methotrex-
ate [18]. Presumably, the time in remission is a pre-
requisite in patients with RA for persisting clinical
benefits after TNFi discontinuation [17]. Accordingly,
withdrawing TNFi later in pregnancy in patients with
sustained inactive disease did not result in a flare in pa-
tients with inflammatory bowel disease [19].
In patients with RA without TNFi, 63.3% of whom
were on pregnancy-compatible disease-modifying drugs,
both the DAS28-CRP scores as well as CRP levels
showed low disease activity during the course of preg-
nancy, and only 26.7% of patients required initiation of
therapy. This confirms that patients with RA with low
disease activity at the first trimester mostly continue
with stable and low disease activity throughout gestation
[3]. By contrast, the possible pregnancy-ameliorating
effect in RA was not strong enough to compensate the
disease aggravation that occurred after TNFi discontinu-
ation around conception. In addition, the subpopulation
of patients treated with TNFi in the period before
Fig. 2 Response to treatment of flares with tumor necrosis factor inhibitor (TNFi) or glucocorticosteroid (GC) treatment in patients with rheumatoid arthritis
(RA) and axial spondyloarthritis (axSpA) during pregnancy. The upper panels show the time course of C-reactive protein (CRP) levels in patients with RA in
whom TNFi treatment (a) or GC treatment (b) was initiated during pregnancy. The lower panels show the time course of CRP levels in patients with axSpA
in whom TNFi treatment (c) or GC treatment (d) was initiated during pregnancy. Box plots present the medians and the interquartile ranges. *P< 0.05
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because symptoms were not sufficiently controlled with
disease-modifying antirheumatic drugs alone. In the lat-
ter patient group, smoldering disease activity might
erupt to disease flares after TNFi discontinuation even
under the tolerance-inducing condition of pregnancy.
Sixty-three percent of patients with axSpA who discon-
tinued TNFi around conception had increased CRP
levels at the second trimester. Disease flares in this
group occurred around gestational week 20, which cor-
responds to the median time to flare of 16 weeks after
discontinuation of TNFi in nonpregnant patients with
axSpA [16]. Patients with axSpA not treated with TNFi
before conception showed stable and low CRP levels but
high ASDAS-CRP scores throughout gestation. The dis-
crepancy could be explained by the composition of the
ASDAS-CRP, which consists of the objective CRP as well
as the subjective parameters [11]. A previous study com-
paring clinical scores and the Medical Outcomes Study
36-item Short Form Health Survey also confirmed the
importance of subjective symptoms resulting in high dis-
ease activity measured in patients with axSpA through-
out pregnancy [20].
The success of new initiation or reintroduction of
therapy for the treatment of flares differed significantly
in pregnant patients with RA and axSpA. In RA, the
start of TNFi because of flare in pregnancy resulted in
improvement and in achievement of disease remission in
the majority of patients. The median CRP levelsdecreased by 69% after the start of therapy and normal-
ized during the third trimester. By contrast, in patients
with axSpA in whom TNFi treatment was initiated, me-
dian CRP levels decreased by only 35%, and CRP levels
remained elevated during pregnancy. Thus, high disease
activity in axSpA could be ameliorated but not con-
trolled by restart or initiation of TNFi in pregnancy. Our
results for patients with RA and axSpA suggest that the
initiation of TNFi during pregnancy may be more effect-
ive in patients with active RA than in patients with ac-
tive axSpA.
GC therapy has been accepted for treating flares of
rheumatic disease during pregnancy [21]. Our study
showed that the response of CRP values to GC treatment
differed in patients with RA and patients with axSpA. Pa-
tients with RA responded with a significant decrease of
disease activity and CRP levels after the start of GC treat-
ment during pregnancy, whereas patients with axSpA
showed a minimal decrease of CRP. This weak response in
patients with axSpA is consistent with the lack of effect of
GC treatment in nonpregnant patients with axSpA [22].
The strength of our study is the prospective design
and the inclusion of two rheumatic diseases with differ-
ent responses to pregnancy. It is the first report on the
effect of discontinuing TNFi in early pregnancy, and on
the response to the restart or the initiation of medication
at a flare in pregnant patients with RA and axSpA. A
limitation is the number of TNFi-treated patients, which
did not allow more detailed statistical analysis.
van den Brandt et al. Arthritis Research & Therapy  (2017) 19:64 Page 8 of 9Conclusions
Elevated disease activity and TNFi discontinuation in
early pregnancy may cause a relapse of disease activity in
patients with RA and axSpA. Restart of medication con-
trols disease activity in pregnant patients with RA but
shows insufficient effect in pregnant patients with
axSpA. The data indicate that tailored medication should
be considered beyond conception to stabilize low disease
activity and to prevent a flare during pregnancy.
Additional file
Additional file 1: Table S1. Risk factors of for severe flares in RA [23]
and axSpA [24] during the course of pregnancy. (DOCX 23 kb)
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